Sevelamer hydrochloride for tumor lysis syndrome-related hyperphosphatemia

被引:0
作者
L Harsha Prasada
机构
[1] Mangalore (Manipal University),From Department of Pediatrics, Kasturba Medical College Hospital
[2] Mangalore,Department of Pediatrics, Kasturba Medical College Hospital
来源
Indian Pediatrics | 2015年 / 52卷
关键词
Acute lymphoblastic leukemia; Hyperphosphatemia; Sevelamer hydrochloride; Tumour lysis syndrome;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:613 / 615
页数:2
相关论文
共 46 条
[1]  
Satyanarayana L(2014)Childhood cancer incidence in India: A review of population-based cancer registries Indian Pediatr. 51 218-20
[2]  
Asthana S(1999)Acute lymphoblastic leukemia in India: An analysis of prognostic factors using a single treatment regimen Ann Oncol. 10 167-76
[3]  
Labani SP(2013)Tumor lysis syndrome Indian J Pediatr 80 50-4
[4]  
Advani S(1997)Poly [allylanmine hydrochloride] (Renagel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure Am J Kidney Dis. 29 66-71
[5]  
Pai S(2003)Sevelamer hydrochloride: An effective phosphate binder in dialyzed children Pediatr Nephrol. 18 1260-4
[6]  
Venzon D(2013)Hyperphosphataemia: Treatment options Drugs. 73 673-88
[7]  
Adde M(2006)A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD Am J Kidney Dis. 47 625-35
[8]  
Kurkure PK(2005)Increase in serum magnesium level in haemodialysis patients receiving sevelamer hydrochloride Int Urol Nephrol. 37 321-8
[9]  
Nair CN(2006)Sevelamer therapy for pediatric end-stage renal disease Pharmacotherapy. 26 410-3
[10]  
Rajendran A(2008)Sevelamer hydrochloride: A novel treatment of hyperphosphatemia associated with tumor lysis syndrome in children Pediatr Blood Cancer. 51 59-61